Applications

Alzheimer's Disease

Assess Alzheimer’s drug efficacy in a human model of amyloid-driven pathology. The CNS-3D Induced Alzheimer’s model enables researchers to induce Alzheimer’s-relevant phenotypes with exogenous amyloid beta and evaluate whether candidates reduce downstream pathology, injury, and functional disruption.

Model Amyloid-Driven Alzheimer’s Pathology

Alzheimer’s disease biology involves complex interactions between amyloid pathology, tau dysregulation, neuroinflammation, neuronal injury, and functional network disruption. The CNS-3D Induced Alzheimer’s model provides the cellular complexity needed to study these interactions, incorporating neurons, astrocytes, and microglia to capture exogenous amyloid beta–driven pathological, inflammatory, and functional changes.

A standardized amyloid beta induction workflow allows researchers to generate reproducible Alzheimer’s-relevant phenotypes and move efficiently from disease modeling to efficacy testing. Integrated pathology, cell health, molecular, cytokine, and functional endpoints support disease modeling and anti-amyloid beta efficacy testing.

Advantages

Evaluate pathology and drug efficacy

Study Alzheimer’s-relevant mechanisms and anti-amyloid beta efficacy in a reproducible human 3D model containing neurons, astrocytes, and microglia.

Amyloid-Driven Disease Induction

Generate reproducible Alzheimer’s-relevant phenotypes using a standardized exogenous amyloid beta workflow.

Multicellular Neuroimmune Model

Capture amyloid beta effects across neurons, astrocytes, and microglia in one 3D model.

Pathology and
Injury Endpoints

Multiplexed assessment of amyloid beta burden, phospho-tau staining, LDH release, cytokine release, and gene expression.

Functional Efficacy Assessment

Quantify amyloid beta–driven disruption of neuronal network activity using high-throughput calcium imaging.

Use Case

Amyloid Beta Pathology

Induce Alzheimer’s-relevant phenotypes—including tau phosphorylation, apoptosis, neuronal network disruption, and gene expression changes—through exogenous amyloid beta exposure in the CNS-3D Induced Alzheimer’s model. This assay enables higher-throughput evaluation of whether drug candidates reduce amyloid-driven pathology and preserve neuronal function.

Amyloid beta oligomers induce concentration-dependent suppression of neuronal network activity, measured by calcium imaging.

Offerings

Products & Services

Investigate amyloid-driven pathology and drug efficacy with assay-ready products for in-house studies or through CNS Services for end-to-end study design, execution, and analysis.